Novel unbiased equations to calculate triglyceride-rich lipoprotein cholesterol from routine non-fasting lipids

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Hermans, Michel P ^a,b   Ahn, Sylvie A ^a   Rousseau, Michel F ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Atherogenic dyslipidemia; Chylomicrons; Diabetes; Lipoprotein; Non fasting; Remnant cholesterol; Triglycerides

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETIC PATIENT; DYSLIPIDEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HUMANS; LIPID METABOLISM; LIPOPROTEINS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; TRIGLYCERIDES;

EID: 84897481560     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-56     Document Type: Article

References (38)

1. Cohn JS, Marcoux C, Davignon J. Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arterioscler Thromb Vasc Biol 1999, 19:2474-2486. 10.1161/01.ATV.19.10.2474, 10521378.
2. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL. American Diabetes Association; American College of Cardiology foundation. Lipoprotein management in patients with cardiometabolic risk. Consensus statement from the American Diabetes Association and the American College of Cardiology foundation. Diabetes Care 2008, 31:811-822. 10.2337/dc08-9018, 18375431.
3. Fujioka Y, Ishikawa Y. Remnant lipoproteins as strong key particles to atherogenesis. J Atheroscler Thromb 2009, 16:145-154. 10.5551/jat.E598, 19556722.
4. Kannel WB, Vasan RS. Triglycerides as vascular risk factors: new epidemiologic insights. Curr Opin Cardiol 2009, 24:345-350. 10.1097/HCO.0b013e32832c1284, 3012388, 19424059.
5. Hermans MP, Fruchart JC. Reducing residual vascular risk in patients with atherogenic dyslipidaemia: where do we go from here?. Clin Lipidol 2010, 5:811-826.
6. Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J, Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010, 375:1634-1639. 2867029, 20452521, Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration.
7. Jacobson TA. Opening a new lipid " apo-thecary" : incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk. Mayo Clin Proc 2011, 86:762-780. 10.4065/mcp.2011.0128, 3146376, 21803958.
8. Langsted A, Freiberg JJ, Tybjaerg-Hansen A, Schnohr P, Jensen GB, Nordestgaard BG. Non-fasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City heart study with 31 years of follow-up. J Intern Med 2011, 270:65-75. 10.1111/j.1365-2796.2010.02333.x, 21198993.
9. Jørgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjærg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J 2013, 34:1826-1833. 10.1093/eurheartj/ehs431, 23248205.
10. McPherson R. Remnant cholesterol: " Non-(HDL-C + LDL-C)" as a coronary artery disease risk factor. J Am Coll Cardiol 2013, 61:437-439. 10.1016/j.jacc.2012.11.009, 23265336.
11. Varbo A, Benn M, Tybjærg-Hansen A, Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013, 61:427-436. 10.1016/j.jacc.2012.08.1026, 23265341.
12. Zambon A, Puato M, Faggin E, Grego F, Rattazzi M, Pauletto P. Lipoprotein remnants and dense LDL are associated with features of unstable carotid plaque: a flag for non-HDL-C. Atherosclerosis 2013, 230:106-109. 10.1016/j.atherosclerosis.2013.06.024, 23958261.
13. Fruchart JC, Duriez P. HDL and triglyceride as therapeutic targets. Curr Opin Lipidol 2002, 13:605-616. 10.1097/00041433-200212000-00003, 12441884.
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
15. Martin SS, Blaha MJ, Toth PP, Joshi PH, McEvoy JW, Ahmed HM, Elshazly MB, Swiger KJ, Michos ED, Kwiterovich PO, Kulkarni KR, Chimera J, Cannon CP, Blumenthal RS, Jones SR. Very large database of lipids: rationale and design. Clin Cardiol 2013, 36:641-648. 10.1002/clc.22214, 24122913.
16. Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS, Jones SR. Comparison of a novel method vs the friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA 2013, 310:2061-2068. 10.1001/jama.2013.280532, 24240933.
17. Planella T, Cortés M, Martínez-Brú C, González-Sastre F, Ordóñez-Llanos J. Calculation of LDL-cholesterol by using apolipoprotein B for classification of nonchylomicronemic dyslipemia. Clin Chem 1997, 43:808-815.
18. Björkegren J, Karpe F, Milne RW, Hamsten A. Differences in apolipoprotein and lipid composition between human chylomicron remnants and very low density lipoproteins isolated from fasting and postprandial plasma. J Lipid Res 1998, 39:1412-1420.
19. Hermans MP, Sacks FM, Ahn SA, Rousseau MF. Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: discriminant Ratio and unbiased equivalence. Cardiovasc Diabetol 2011, 10:20. 10.1186/1475-2840-10-20, 3056766, 21356116.
20. Bairaktari E, Hatzidimou K, Tzallas C, Vini M, Katsaraki A, Tselepis A, Elisaf M, Tsolas O. Estimation of LDL cholesterol based on the friedewald formula and on apo B levels. Clin Biochem 2000, 33:549-555. 10.1016/S0009-9120(00)00162-4, 11124340.
21. Martin SS, Blaha MJ, Elshazly MB, Brinton EA, Toth PP, McEvoy JW, Joshi PH, Kulkarni KR, Mize PD, Kwiterovich PO, Defilippis AP, Blumenthal RS, Jones SR. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol 2013, 62:732-739. 10.1016/j.jacc.2013.01.079, 23524048.
22. Levy JC, Morris RJ, Hammersley M, Turner RC. Discrimination, adjusted correlation, and equivalence of imprecise tests: application to glucose tolerance. Am J Physiol 1999, 276:E365-E375.
23. Hermans MP, Levy JC, Morris RJ, Turner RC. Comparison of insulin sensitivity tests across a range of glucose tolerance form normal to diabetes. Diabetologia 1999, 42:678-687. 10.1007/s001250051215, 10382587.
24. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC. International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645. 10.1161/CIRCULATIONAHA.109.192644, 19805654.
25. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999, 130:461-470. 10.7326/0003-4819-130-6-199903160-00002, 10075613.
26. Hermans MP, Ahn SA, Rousseau MF. The multi-faceted outcomes of conjunct diabetes and cardiovascular familial history in type 2 diabetes. J Diabetes Complications 2012, 26:187-194. 10.1016/j.jdiacomp.2012.03.014, 22521319.
27. Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, Holman RR. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective diabetes study risk engine. Stroke 2002, 33:1776-1781. 10.1161/01.STR.0000020091.07144.C7, 12105351.
28. Hermans MP, Ahn SA, Rousseau MF. Log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males. Cardiovasc Diabetol 2010, 9:88. 10.1186/1475-2840-9-88, 3020173, 21156040.
29. Hermans MP, Ahn SA, Rousseau MF. The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, β-cell function loss and microangiopathy in type 2 diabetes females. Lipids Health Dis 2012, 11:132. 10.1186/1476-511X-11-132, 3539971, 23046637.
30. Querton L, Buysschaert M, Hermans MP. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels. J Clin Lipidol 2012, 6:434-442. 10.1016/j.jacl.2012.04.002, 23009779.
31. Murase T, Okubo M, Takeuchi I. Non-HDL-cholesterol/apolipoprotein B ratio: a useful distinguishing feature in the screening for type III hyperlipoproteinemia. J Clin Lipidol 2010, 4:99-104. 10.1016/j.jacl.2010.01.004, 21122636.
32. Hermans MP, Ahn SA, Rousseau MF, Zimering MB. Residual vascular risk in T2DM: the next frontier. Recent Advances in the Pathogenesis, Prevention and Management of Type 2 Diabetes and its Complications 2011, 45-66. Rijeka (Croatia): Intech.
33. Bestehorn K, Smolka W, Pittrow D, Schulte H, Assmann G. Atherogenic dyslipidemia as evidenced by the lipid triad: prevalence and associated risk in statin-treated patients in ambulatory care. Curr Med Res Opin 2010, 26:2833-2839. 10.1185/03007995.2010.532088, 21058895.
34. Fruchart JC, Sacks FM, Hermans MP. International Steering Committee of R(3)i. Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i). Curr Med Res Opin 2010, 26:1793-1797. 10.1185/03007995.2010.489341, 20482323.
35. Reyes-Soffer G, Ngai CI, Lovato L, Karmally W, Ramakrishnan R, Holleran S, Ginsberg HN. Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care 2013, 36:422-428. 10.2337/dc11-2556, 3554305, 23033246.
36. Hermans MP, Ahn SA, Rousseau MF. The non-HDL-C/HDL-C ratio provides cardiovascular risk stratification similar to the ApoB/ApoA1 ratio in diabetics: Comparison with reference lipid markers. Diabetes Metab Syndr 2007, 1:23-28.
37. Tenenbaum A, Fisman EZ. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol 2012, 11:125. 10.1186/1475-2840-11-125, 3489608, 23057687.
38. Fruchart JC, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, Barter P, Betteridge J, Bruckert E, Cuevas A, Farnier M, Ferrannini E, Fioretto P, Genest J, Ginsberg HN, Gotto AM, Hu D, Kadowaki T, Kodama T, Krempf M, Matsuzawa Y, Núñez-Cortés JM, Monfil CC, Ogawa H, Plutzky J, Rader DJ, Sadikot S, Santos RD, Shlyakhto E, Sritara P, Sy R, Tall A, Tan CE, Tokgözoǧlu L, Toth PP, Valensi P, Wanner C, Zambon A, Zhu J, Zimmet P. Residual risk reduction initiative (R3i). Residual macrovascular risk in 2013: what have we learned?. Cardiovasc Diabetol 2014, 13:26. 10.1186/1475-2840-13-26, 3922777, 24460800.